• Spyglass Pharma outlined Phase 3 pivotal trials underway for BIM-IOL System, an intraocular lens drug-delivery product designed to provide about 3 years of bimatoprost therapy for open-angle glaucoma or ocular hypertension at time of routine cataract surgery.
• First-in-human feasibility data showed 95% of patients off topical IOP-lowering therapy at 36 months, with 37% mean IOP reduction across doses.
• Phase 1/2 results with intended commercial dose of 78 mcg showed 98% of patients off topical IOP-lowering therapy at 12 months, with 34% mean IOP reduction.
• Company pegged BIM-IOL System addressable U.S. market at about USD 13 billion, citing an estimated 1,000,000 U.S. glaucoma or ocular hypertension patients projected to undergo cataract surgery in 2025.
• Cash and cash equivalents and short-term investments totaled USD 251 million as of March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.